Please Wait.....
Report
mRNA Vaccines and RNAi Therapeutics Market By Disease Type (Hereditary transthyretin-mediated amyloidosis genetic, Acute hepatic porphyria, Primary hyperoxaluria type 1, Atherosclerotic cardiovascular disease), By Route of administration (IV infusion, Subcutaneous), By End user (Research Institutes, Hospitals and clinics): Global Opportunity Analysis and Industry Forecast, 2021-2031
Market Report I 2022-07-01 I 234 Pages I Allied Market Research
The single protein-coding gene known as messenger ribonucleic acid (mRNA) is located in the genome and provides the basis for how cells make proteins. Mammalian cells are used in the laboratory to create mRNA vaccines and treatments, which have positive immunological properties. Some of the most common types of vaccines and therapies include non-replicating, in vivo self-replicating, self-amplifying, and in-vitro dendritic cell non-replicating mRNA. They are administered intravenously to trigger the immune system's virus-detection mechanisms and trigger the production of viral antigen proteins by the cells. The body's immunity is strengthened through enhancing B- and T-cell responses.
The major factors that drive the growth of the global mRNA vaccines and RNAi therapeutics market include increase in awareness about vaccination, increase in prevalence of cancer and cardiovascular disease and initiatives taken by government for large scale sequencing projects. In addition, target specialty and selectivity of treatment further propel the market growth. However, high cost of research, threat of failure and challenges in quantification of mRNA are expected to restrain the growth of the mRNA vaccines and RNAi therapeutics market during the forecast period. Conversely, application of mRNA technology and development of mRNA biomarker are anticipated to provide lucrative opportunities to the market players.
The mRNA vaccines and RNAi therapeutics market is segmented into disease type, route of administration, end user and region. According to disease type, the market is categorized into hereditary transthyretin-mediated amyloidosis genetic, acute hepatic porphyria, primary hyperoxaluria type 1 and atherosclerotic cardiovascular disease. On the basis of route of administration, it is segmented into IV infusion and subcutaneous. By end user, it is segregated into research institute and hospitals and clinics. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include the Alnylam Pharmaceuticals, BioNTech AG, CureVac AG, eTheRNA Immunotherapy, Ethris GmbH, In-Cell-Art, Moderna Therapeutics, Sangamon therapeutic Inc., Sanofi AG, SCM Lifescience Co., Ltd, Sarepta Therapeutics, Arcturus Therapeutics, Ionis pharmaceuticals Inc., Nutcracker Therapeutics, and TIBA Biotech.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the mRNA vaccines and RNAi therapeutics market analysis from 2021 to 2031 to identify the prevailing mrna vaccines and rnai therapeutics market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the mRNA vaccines and RNAitherapeutics market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global mRNA vaccines and RNAitherapeutics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Disease Type
- Hereditary transthyretin-mediated amyloidosis genetic
- Acute hepatic porphyria
- Primary hyperoxaluria type 1
- Atherosclerotic cardiovascular disease
By Route of administration
- IV infusion
- Subcutaneous
By End user
- Research Institutes
- Hospitals and clinics
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Alnylam Pharmaceuticals
- BioNTech AG
- Curevac AG
- Etherna Immunotherapies
- Ethris GMBH
- IN-CELL-ART
- Moderna Therapeutics
- Sangamo Therapeutics, Inc.
- Sanofi AG
- SCM Life Sciences (Argos Therapeutics, Inc. )
- Sarepta Therapeutics
- Arcturus Therapeutics
- Ionis Pharmaceuticals, Inc
- Nutcracker
- Tiba Biotech
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Hereditary transthyretin-mediated amyloidosis genetic
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Acute hepatic porphyria
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Primary hyperoxaluria type 1
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Atherosclerotic cardiovascular disease
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
CHAPTER 5: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
5.1 Overview
5.1.1 Market size and forecast
5.2 IV infusion
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Subcutaneous
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2 Research Institutes
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Hospitals and clinics
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
CHAPTER 7: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Disease Type
7.2.3 North America Market size and forecast, by Route of administration
7.2.4 North America Market size and forecast, by End user
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Disease Type
7.2.5.1.2 Market size and forecast, by Route of administration
7.2.5.1.3 Market size and forecast, by End user
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Disease Type
7.2.5.2.2 Market size and forecast, by Route of administration
7.2.5.2.3 Market size and forecast, by End user
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Disease Type
7.2.5.3.2 Market size and forecast, by Route of administration
7.2.5.3.3 Market size and forecast, by End user
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Disease Type
7.3.3 Europe Market size and forecast, by Route of administration
7.3.4 Europe Market size and forecast, by End user
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Disease Type
7.3.5.1.2 Market size and forecast, by Route of administration
7.3.5.1.3 Market size and forecast, by End user
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Disease Type
7.3.5.2.2 Market size and forecast, by Route of administration
7.3.5.2.3 Market size and forecast, by End user
7.3.5.3 U.K.
7.3.5.3.1 Market size and forecast, by Disease Type
7.3.5.3.2 Market size and forecast, by Route of administration
7.3.5.3.3 Market size and forecast, by End user
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Disease Type
7.3.5.4.2 Market size and forecast, by Route of administration
7.3.5.4.3 Market size and forecast, by End user
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Disease Type
7.3.5.5.2 Market size and forecast, by Route of administration
7.3.5.5.3 Market size and forecast, by End user
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Disease Type
7.3.5.6.2 Market size and forecast, by Route of administration
7.3.5.6.3 Market size and forecast, by End user
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Disease Type
7.4.3 Asia-Pacific Market size and forecast, by Route of administration
7.4.4 Asia-Pacific Market size and forecast, by End user
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 China
7.4.5.1.1 Market size and forecast, by Disease Type
7.4.5.1.2 Market size and forecast, by Route of administration
7.4.5.1.3 Market size and forecast, by End user
7.4.5.2 Japan
7.4.5.2.1 Market size and forecast, by Disease Type
7.4.5.2.2 Market size and forecast, by Route of administration
7.4.5.2.3 Market size and forecast, by End user
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Disease Type
7.4.5.3.2 Market size and forecast, by Route of administration
7.4.5.3.3 Market size and forecast, by End user
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Disease Type
7.4.5.4.2 Market size and forecast, by Route of administration
7.4.5.4.3 Market size and forecast, by End user
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Disease Type
7.4.5.5.2 Market size and forecast, by Route of administration
7.4.5.5.3 Market size and forecast, by End user
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Disease Type
7.4.5.6.2 Market size and forecast, by Route of administration
7.4.5.6.3 Market size and forecast, by End user
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Disease Type
7.5.3 LAMEA Market size and forecast, by Route of administration
7.5.4 LAMEA Market size and forecast, by End user
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Disease Type
7.5.5.1.2 Market size and forecast, by Route of administration
7.5.5.1.3 Market size and forecast, by End user
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Disease Type
7.5.5.2.2 Market size and forecast, by Route of administration
7.5.5.2.3 Market size and forecast, by End user
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Disease Type
7.5.5.3.2 Market size and forecast, by Route of administration
7.5.5.3.3 Market size and forecast, by End user
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Disease Type
7.5.5.4.2 Market size and forecast, by Route of administration
7.5.5.4.3 Market size and forecast, by End user
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Alnylam Pharmaceuticals
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 BioNTech AG
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Curevac AG
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Etherna Immunotherapies
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Ethris GMBH
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 IN-CELL-ART
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Moderna Therapeutics
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Sangamo Therapeutics, Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Sanofi AG
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 SCM Life Sciences (Argos Therapeutics, Inc. )
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Sarepta Therapeutics
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 Arcturus Therapeutics
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments
9.13 Ionis Pharmaceuticals, Inc
9.13.1 Company overview
9.13.2 Company snapshot
9.13.3 Operating business segments
9.13.4 Product portfolio
9.13.5 Business performance
9.13.6 Key strategic moves and developments
9.14 Nutcracker
9.14.1 Company overview
9.14.2 Company snapshot
9.14.3 Operating business segments
9.14.4 Product portfolio
9.14.5 Business performance
9.14.6 Key strategic moves and developments
9.15 Tiba Biotech
9.15.1 Company overview
9.15.2 Company snapshot
9.15.3 Operating business segments
9.15.4 Product portfolio
9.15.5 Business performance
9.15.6 Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 2. MRNA VACCINES AND RNAI THERAPEUTICS MARKET SIZE, FOR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS GENETIC, BY REGION, 2021-2031 ($MILLION)
TABLE 3. MRNA VACCINES AND RNAI THERAPEUTICS MARKET FOR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS GENETIC BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. MRNA VACCINES AND RNAI THERAPEUTICS MARKET SIZE, FOR ACUTE HEPATIC PORPHYRIA, BY REGION, 2021-2031 ($MILLION)
TABLE 5. MRNA VACCINES AND RNAI THERAPEUTICS MARKET FOR ACUTE HEPATIC PORPHYRIA BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. MRNA VACCINES AND RNAI THERAPEUTICS MARKET SIZE, FOR PRIMARY HYPEROXALURIA TYPE 1, BY REGION, 2021-2031 ($MILLION)
TABLE 7. MRNA VACCINES AND RNAI THERAPEUTICS MARKET FOR PRIMARY HYPEROXALURIA TYPE 1 BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. MRNA VACCINES AND RNAI THERAPEUTICS MARKET SIZE, FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, BY REGION, 2021-2031 ($MILLION)
TABLE 9. MRNA VACCINES AND RNAI THERAPEUTICS MARKET FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE BY COUNTRY, 2021-2031 ($MILLION)
TABLE 10. GLOBAL MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 11. MRNA VACCINES AND RNAI THERAPEUTICS MARKET SIZE, FOR IV INFUSION, BY REGION, 2021-2031 ($MILLION)
TABLE 12. MRNA VACCINES AND RNAI THERAPEUTICS MARKET FOR IV INFUSION BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. MRNA VACCINES AND RNAI THERAPEUTICS MARKET SIZE, FOR SUBCUTANEOUS, BY REGION, 2021-2031 ($MILLION)
TABLE 14. MRNA VACCINES AND RNAI THERAPEUTICS MARKET FOR SUBCUTANEOUS BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. GLOBAL MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 16. MRNA VACCINES AND RNAI THERAPEUTICS MARKET SIZE, FOR RESEARCH INSTITUTES, BY REGION, 2021-2031 ($MILLION)
TABLE 17. MRNA VACCINES AND RNAI THERAPEUTICS MARKET FOR RESEARCH INSTITUTES BY COUNTRY, 2021-2031 ($MILLION)
TABLE 18. MRNA VACCINES AND RNAI THERAPEUTICS MARKET SIZE, FOR HOSPITALS AND CLINICS, BY REGION, 2021-2031 ($MILLION)
TABLE 19. MRNA VACCINES AND RNAI THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS BY COUNTRY, 2021-2031 ($MILLION)
TABLE 20. MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 21. NORTH AMERICA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 22. NORTH AMERICA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 23. NORTH AMERICA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 24. NORTH AMERICA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 25. U.S. MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 26. U.S. MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 27. U.S. MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 28. CANADA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 29. CANADA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 30. CANADA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 31. MEXICO MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 32. MEXICO MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 33. MEXICO MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 34. EUROPE MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 35. EUROPE MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 36. EUROPE MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 37. EUROPE MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 38. GERMANY MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 39. GERMANY MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 40. GERMANY MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 41. FRANCE MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 42. FRANCE MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 43. FRANCE MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 44. U.K. MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 45. U.K. MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 46. U.K. MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 47. ITALY MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 48. ITALY MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 49. ITALY MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 50. SPAIN MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 51. SPAIN MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 52. SPAIN MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 53. REST OF EUROPE MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 54. REST OF EUROPE MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 55. REST OF EUROPE MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 56. ASIA-PACIFIC MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 57. ASIA-PACIFIC MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 58. ASIA-PACIFIC MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 59. ASIA-PACIFIC MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 60. CHINA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 61. CHINA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 62. CHINA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 63. JAPAN MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 64. JAPAN MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 65. JAPAN MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 66. INDIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 67. INDIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 68. INDIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 69. AUSTRALIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 70. AUSTRALIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 71. AUSTRALIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 72. SOUTH KOREA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 73. SOUTH KOREA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 74. SOUTH KOREA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 75. REST OF ASIA-PACIFIC MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 76. REST OF ASIA-PACIFIC MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 77. REST OF ASIA-PACIFIC MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 78. LAMEA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 79. LAMEA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 80. LAMEA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 81. LAMEA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 82. BRAZIL MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 83. BRAZIL MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 84. BRAZIL MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 85. SAUDI ARABIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 86. SAUDI ARABIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 87. SAUDI ARABIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 88. SOUTH AFRICA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 89. SOUTH AFRICA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 90. SOUTH AFRICA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 91. REST OF LAMEA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 92. REST OF LAMEA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 93. REST OF LAMEA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 94.ALNYLAM PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 95.ALNYLAM PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 96.ALNYLAM PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 97.ALNYLAM PHARMACEUTICALS: NET SALES,
TABLE 98.ALNYLAM PHARMACEUTICALS: KEY STRATERGIES
TABLE 99.BIONTECH AG: COMPANY SNAPSHOT
TABLE 100.BIONTECH AG: OPERATING SEGMENTS
TABLE 101.BIONTECH AG: PRODUCT PORTFOLIO
TABLE 102.BIONTECH AG: NET SALES,
TABLE 103.BIONTECH AG: KEY STRATERGIES
TABLE 104.CUREVAC AG: COMPANY SNAPSHOT
TABLE 105.CUREVAC AG: OPERATING SEGMENTS
TABLE 106.CUREVAC AG: PRODUCT PORTFOLIO
TABLE 107.CUREVAC AG: NET SALES,
TABLE 108.CUREVAC AG: KEY STRATERGIES
TABLE 109.ETHERNA IMMUNOTHERAPIES: COMPANY SNAPSHOT
TABLE 110.ETHERNA IMMUNOTHERAPIES: OPERATING SEGMENTS
TABLE 111.ETHERNA IMMUNOTHERAPIES: PRODUCT PORTFOLIO
TABLE 112.ETHERNA IMMUNOTHERAPIES: NET SALES,
TABLE 113.ETHERNA IMMUNOTHERAPIES: KEY STRATERGIES
TABLE 114.ETHRIS GMBH: COMPANY SNAPSHOT
TABLE 115.ETHRIS GMBH: OPERATING SEGMENTS
TABLE 116.ETHRIS GMBH: PRODUCT PORTFOLIO
TABLE 117.ETHRIS GMBH: NET SALES,
TABLE 118.ETHRIS GMBH: KEY STRATERGIES
TABLE 119.IN-CELL-ART: COMPANY SNAPSHOT
TABLE 120.IN-CELL-ART: OPERATING SEGMENTS
TABLE 121.IN-CELL-ART: PRODUCT PORTFOLIO
TABLE 122.IN-CELL-ART: NET SALES,
TABLE 123.IN-CELL-ART: KEY STRATERGIES
TABLE 124.MODERNA THERAPEUTICS: COMPANY SNAPSHOT
TABLE 125.MODERNA THERAPEUTICS: OPERATING SEGMENTS
TABLE 126.MODERNA THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 127.MODERNA THERAPEUTICS: NET SALES,
TABLE 128.MODERNA THERAPEUTICS: KEY STRATERGIES
TABLE 129.SANGAMO THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 130.SANGAMO THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE 131.SANGAMO THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 132.SANGAMO THERAPEUTICS, INC.: NET SALES,
TABLE 133.SANGAMO THERAPEUTICS, INC.: KEY STRATERGIES
TABLE 134.SANOFI AG: COMPANY SNAPSHOT
TABLE 135.SANOFI AG: OPERATING SEGMENTS
TABLE 136.SANOFI AG: PRODUCT PORTFOLIO
TABLE 137.SANOFI AG: NET SALES,
TABLE 138.SANOFI AG: KEY STRATERGIES
TABLE 139.SCM LIFE SCIENCES (ARGOS THERAPEUTICS, INC. ): COMPANY SNAPSHOT
TABLE 140.SCM LIFE SCIENCES (ARGOS THERAPEUTICS, INC. ): OPERATING SEGMENTS
TABLE 141.SCM LIFE SCIENCES (ARGOS THERAPEUTICS, INC. ): PRODUCT PORTFOLIO
TABLE 142.SCM LIFE SCIENCES (ARGOS THERAPEUTICS, INC. ): NET SALES,
TABLE 143.SCM LIFE SCIENCES (ARGOS THERAPEUTICS, INC. ): KEY STRATERGIES
TABLE 144.SAREPTA THERAPEUTICS: COMPANY SNAPSHOT
TABLE 145.SAREPTA THERAPEUTICS: OPERATING SEGMENTS
TABLE 146.SAREPTA THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 147.SAREPTA THERAPEUTICS: NET SALES,
TABLE 148.SAREPTA THERAPEUTICS: KEY STRATERGIES
TABLE 149.ARCTURUS THERAPEUTICS: COMPANY SNAPSHOT
TABLE 150.ARCTURUS THERAPEUTICS: OPERATING SEGMENTS
TABLE 151.ARCTURUS THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 152.ARCTURUS THERAPEUTICS: NET SALES,
TABLE 153.ARCTURUS THERAPEUTICS: KEY STRATERGIES
TABLE 154.IONIS PHARMACEUTICALS, INC: COMPANY SNAPSHOT
TABLE 155.IONIS PHARMACEUTICALS, INC: OPERATING SEGMENTS
TABLE 156.IONIS PHARMACEUTICALS, INC: PRODUCT PORTFOLIO
TABLE 157.IONIS PHARMACEUTICALS, INC: NET SALES,
TABLE 158.IONIS PHARMACEUTICALS, INC: KEY STRATERGIES
TABLE 159.NUTCRACKER: COMPANY SNAPSHOT
TABLE 160.NUTCRACKER: OPERATING SEGMENTS
TABLE 161.NUTCRACKER: PRODUCT PORTFOLIO
TABLE 162.NUTCRACKER: NET SALES,
TABLE 163.NUTCRACKER: KEY STRATERGIES
TABLE 164.TIBA BIOTECH: COMPANY SNAPSHOT
TABLE 165.TIBA BIOTECH: OPERATING SEGMENTS
TABLE 166.TIBA BIOTECH: PRODUCT PORTFOLIO
TABLE 167.TIBA BIOTECH: NET SALES,
TABLE 168.TIBA BIOTECH: KEY STRATERGIES
LIST OF FIGURES
FIGURE 1.MRNA VACCINES AND RNAI THERAPEUTICS MARKET SEGMENTATION
FIGURE 2.MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031
FIGURE 3.MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.MRNA VACCINES AND RNAI THERAPEUTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.MRNA VACCINES AND RNAI THERAPEUTICS MARKET,BY DISEASE TYPE,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS GENETIC MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ACUTE HEPATIC PORPHYRIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF PRIMARY HYPEROXALURIA TYPE 1 MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031(%)
FIGURE 17.MRNA VACCINES AND RNAI THERAPEUTICS MARKET,BY ROUTE OF ADMINISTRATION,2021(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF IV INFUSION MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF SUBCUTANEOUS MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031(%)
FIGURE 20.MRNA VACCINES AND RNAI THERAPEUTICS MARKET,BY END USER,2021(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF RESEARCH INSTITUTES MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOSPITALS AND CLINICS MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031(%)
FIGURE 23.MRNA VACCINES AND RNAI THERAPEUTICS MARKET BY REGION,2021
FIGURE 24.U.S. MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 25.CANADA MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 26.MEXICO MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 27.GERMANY MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 28.FRANCE MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 29.U.K. MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 30.ITALY MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 31.SPAIN MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 32.REST OF EUROPE MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 33.CHINA MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 34.JAPAN MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 35.INDIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 36.AUSTRALIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 37.SOUTH KOREA MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 38.REST OF ASIA-PACIFIC MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 39.BRAZIL MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 40.SAUDI ARABIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 41.SOUTH AFRICA MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 42.REST OF LAMEA MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 46.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 47.COMPETITIVE DASHBOARD
FIGURE 48.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 49.ALNYLAM PHARMACEUTICALS.: NET SALES ,($MILLION)
FIGURE 50.BIONTECH AG.: NET SALES ,($MILLION)
FIGURE 51.CUREVAC AG.: NET SALES ,($MILLION)
FIGURE 52.ETHERNA IMMUNOTHERAPIES.: NET SALES ,($MILLION)
FIGURE 53.ETHRIS GMBH.: NET SALES ,($MILLION)
FIGURE 54.IN-CELL-ART.: NET SALES ,($MILLION)
FIGURE 55.MODERNA THERAPEUTICS.: NET SALES ,($MILLION)
FIGURE 56.SANGAMO THERAPEUTICS, INC..: NET SALES ,($MILLION)
FIGURE 57.SANOFI AG.: NET SALES ,($MILLION)
FIGURE 58.SCM LIFE SCIENCES (ARGOS THERAPEUTICS, INC. ).: NET SALES ,($MILLION)
FIGURE 59.SAREPTA THERAPEUTICS.: NET SALES ,($MILLION)
FIGURE 60.ARCTURUS THERAPEUTICS.: NET SALES ,($MILLION)
FIGURE 61.IONIS PHARMACEUTICALS, INC.: NET SALES ,($MILLION)
FIGURE 62.NUTCRACKER.: NET SALES ,($MILLION)
FIGURE 63.TIBA BIOTECH.: NET SALES ,($MILLION)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security